#Dana-Farber Cancer Institute

A combination of two immunotherapy drugs showed efficacy in the treatment of advanced melanoma in a phase 3 clinical trial.

A look at the symptoms, treatments, risk factors, prognosis and research on breast cancer metastasis to the brain.

P-NET is a “biologically informed deep learning model” capable of guessing a prostate cancer patient’s disease state.

Study is first to show benefit of any targeted drugs in glioblastomas—the most aggressive brain tumor.

Study findings from the Dana-Farber Cancer Institute arrive as colorectal cancer rates are increasing among younger people.

These findings highlight the importance of mutation-specific care in MPN, not only at diagnosis but in treatment counseling and follow-up.

Researchers looking at ovarian cancer cells that resist chemotherapy hope to develop new therapeutic strategies.

African Americans are twice as likely to be diagnosed with multiple myeloma as white people, but lag in treatment gains.

The hope is that de-identified data sent to the Count Me In initiative will lead to better knowledge and therapies.

Keytruda after kidney cancer surgery prolonged disease-free survival rates in patients at high risk for recurrence.

Rachel Slater insists that the hardest part about going to Harvard was getting in — if you don’t count her two bouts with brain cancer.

During the first two years after diagnosis, one third of breast cancer patients said fertility concerns affected their treatment decisions.

Tumor-infiltrating lymphocytes are T cells that know how to recognize and fight cancer.

Here are six ways that cancer uniquely affects LGBTQ+ individuals.

While battling glioblastoma, Eric Smith feared he wouldn’t get to see his daughter grow up. He’s had the chance thanks to a clinical trial.

Oncologists should take gender identity into account in making decisions about cancer treatment.